Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
What Is a Hepatitis C Drug Worth?

The founder of the company that discovered the Sovaldi hepatitis C drug, which has been listed with a cost of $1,000 for a single pill, says that it’s fairly cheap to make the basic ingredients for this well-regarded new medicine. It may cost only about $1,400 to manufacture a 12-week supply, or 84 pills.

Published
14 January 2014
From
Roll Call
Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

Achillion anticipates the initiation of an all-oral Phase 2 combination study evaluating ACH-3422 by year-end 2014, and anticipates the initiation of a Phase 2 combination study evaluating ACH-3422 and ACH-3102, with and without an Achillion NS3/4A protease inhibitor, in treatment-naive HCV patients over treatment durations of 8 weeks or less in early 2015.

Published
14 January 2014
From
Achillion press release
Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C

In an intent-to-treat analysis, the sustained viral response rate four weeks after the completion of treatment (SVR4) was 83 percent (10 of 12) in treatment-naive genotype 1 patients who received 200 mg of VX-135 in combination with daclatasvir.

Published
09 January 2014
From
Vertex press release
Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency

The application seeks the approval of daclatasvir for use in combination with other agents, including sofosbuvir, for the treatment of chronic hepatitis C genotypes 1, 2, 3 and 4.

Published
08 January 2014
From
Bristol-Myers Squibb press release
$1000 Pill For Hepatitis C Spurs Debate Over Drug Prices

Some activists are beginning to complain about Gilead's decision to charge so much for sofosbuvir.

Published
06 January 2014
From
NPR (blog)
Gilead Sciences, Inc. (GILD): Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014

Gilead Sciences (GILD) received approval earlier this month for what may well be one of the most successful drugs to be approved in years-- Sovaldi, its novel hepatitis drug. Sovaldi, which some analysts say can actually cure some hepatitis cases, is expected to be a blockbuster for the company and could see sales surpassing $8 billion annually by 2018. On the heels of the approval, Gilead announced that it will now seek U.S. approval for a combination of Sovaldi and its newest hepatitis drug -- ledipasvir -- in the first quarter of 2014. The combination of these two drugs could be a "one-two knockout"… not just of the disease, but of the competition as well.

Published
03 January 2014
From
Seeking Alpha
Stellar hepatitis C data puts Gilead farther ahead of pack

Gilead Sciences Inc released impressive late-stage data Wednesday for its once-daily combination pill to treat hepatitis C, advancing its lead in the race to develop new, all-oral treatments for the liver disease, and pushed up its timeline.

Published
24 December 2013
From
Reuters
Life-saving hepatitis C drug approved, but cost is high

Following approvals in the US and Europe this month of a new drug to treat hepatitis C, activists are pushing for the medication to be made available in poor countries.

Published
24 December 2013
From
IRIN Plus News
Egyptians hold their breath as new Hepatitis C drugs promise cure

In Egypt, millions suffering from genotype 4 Hepatitis C count the days until the official approval of new breakthrough drugs, hoping for affordable prices.

Published
24 December 2013
From
Ahram Online
Gilead two-drug hep C combination cures 94% of genotype 1 patients in eight weeks

A two-drug combination of sofosbuvir and ledipasvir cured 94% of previously untreated patients with genotype 1 hepatitis C infection after eight weeks, without the need for ribavirin,

Published
18 December 2013
By
Keith Alcorn

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.